Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-05-11-Speech-3-710-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110511.39.3-710-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"Madam President, first, I would like to emphasise that the Commission is fully aware of, and correspondingly concerned by, the threat to public health posed by antimicrobial resistance (AMR).
In reply to the first question, in 2009, the Commission asked the European Medicines Agency (EMA) to take a lead in collecting comparable data on the use of antimicrobials in animals. The project, the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC), started in the third quarter of 2009. The EMA has worked together with the Member States, EU agencies and relevant stakeholders to develop the system. Findings from the data available from 10 Member States will be published as soon as possible. Twelve additional Member States are voluntarily starting to collect these data. The aim is to broaden the system to cover all EU Member States. A further aim is to have data on a more detailed level – at animal species level, for example.
Why do we need these data? We need them in order to adopt a science-based approach: only on the basis of this type of data can scientists properly assess the true risk of AMR attributed to the use of antimicrobials in animals.
Turning to the second question, I can assure the honourable Members that the Commission is aware that the control of AMR requires a multi-disciplinary approach. Therefore, the Commission consults its own services, Member States’ relevant agencies and other stakeholders on an ongoing basis, for example, through meetings and public consultations. The Commission is working on AMR in close collaboration with its relevant agencies, in particular, the European Centre for Disease Prevention and Control, the European Food Safety Authority, the EMA and the European Union Reference Laboratory for AMR.
In reply to the third and last question, I would like to announce that the Commission is developing a five-year strategy on AMR. This strategy will adopt a holistic approach and will contain concrete proposals for further action to address the issue of AMR in relation to public and animal health. The strategy will be based on the Council conclusions and recommendations on AMR and on the outcome of the consultations I have already mentioned.
Work on the revision of EU rules on veterinary medicinal products and medicated feeding stuffs is ongoing. New tools and instruments to tackle AMR are being considered, for example, as options in the impact assessment.
Based on the evidence gathered, the Commission will decide the details of its legal proposal. Our objective is to present this Commission strategy on 18 November 2011, which will be European Antibiotic Awareness Day."@en1
|
| lpv:unclassifiedMetadata | |
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples